Categories AlphaGraphs, Earnings, Health Care
A visual representation of Johnson & Johnson (JNJ) Q1 2020 earnings results
Johnson & Johnson (NYSE: JNJ) reported that its first-quarter 2020 earnings and revenue came in above the analysts’ expectations citing product sales as well as lower costs and expenses. Region-wise, sales were better in the US than international. The Consumer and Pharmaceutical segments experienced solid high-single-digit growths despite declines in the Medical Devices segment.
The company is mobilizing its resources in the fight against the COVID-19 pandemic. The impact of COVID-19 has been included in the guidance. The reported sales outlook for fiscal 2020 was lowered to $77.5-80.5 billion from $85.4-86.2 billion. Adjusted earnings guidance was reduced to $7.50-7.90 from $8.95-9.10.
Past Performance
4Q19 
3Q19 
2Q19
Most Popular
Earnings Preview: Costco (COST) looks poised to end fiscal 2024 on a high note
Costco Wholesale Corporation (NASDAQ: COST), which operates a chain of membership warehouses, will unveil its fourth-quarter results on the evening of September 26. It has a good track record of
Key takeaways from General Mills’ (GIS) Q1 2025 earnings report
Shares of General Mills, Inc. (NYSE: GIS) gained over 1% on Wednesday after the company’s announcement of its first quarter 2025 earnings results. Revenue came in line with estimates while
GIS Earnings: All you need to know about General Mills’ Q1 2025 earnings results
General Mills, Inc. (NYSE: GIS) reported its first quarter 2025 earnings results today. Net sales decreased 1% year-over-year to $4.8 billion. Organic sales were down 1%. Net earnings attributable to
Comments